Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

1. Methylphenidate remains first-choice drug treatment for children and young people with ADHD

Methylphenidate remains first-choice drug treatment for children and young people with ADHD Methylphenidate remains first-choice drug treatment for children and young people with ADHD Dissemination Centre Discover Portal NIHR DC Discover Methylphenidate remains first-choice drug treatment for children and young people with ADHD Published on 6 November 2018 doi: The stimulant methylphenidate has the best balance of effectiveness against side effects in children and young people (...) or development. It is thought to affect around 5% of children worldwide and is more common in boys than girls. Many children improve with behavioural interventions and family support, with drug treatments reserved for more those more severely affected. Drug treatments include stimulants (such as methylphenidate and amphetamines) and non-stimulants (such as atomoxetine). This review aimed to compare the available drugs using a network meta-analysis. This type of analysis can weigh up the effectiveness

NIHR Dissemination Centre2018

2. Efficacy of Methylphenidate in the Geriatric Population for Fall Prevention

Efficacy of Methylphenidate in the Geriatric Population for Fall Prevention "Efficacy of Methylphenidate in the Geriatric Population for Fall Preve" by Adam Stapleton < > > > > > Title Author Date of Graduation Summer 8-11-2018 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract || Abstract || Background: Approximately one-third of people aged 65 years and over who are not living in institutions fall at least once a year, with higher rates (...) among those living in institutions. One half of older adults who are hospitalized as a result of a fall survive one year later.The importance of fall prevention in older adults is well researched, with many established community based programs in the United States focusing on exercise and fundamental education for fall reduction. However, new options for prevention are being explored. Executive function and gait, both related to falls, may be improved by methylphenidate, providing a promising option

Pacific University EBM Capstone Project2018

3. Methylphenidate

Methylphenidate Top results for methylphenidate - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for methylphenidate The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

4. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude (...) of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events. OBJECTIVES: To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non-randomised studies. SEARCH METHODS: In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO

Cochrane2018

5. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer`s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial

Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer`s Disease: A Double-Blind, Randomized, Placebo-Controlled Trial 28945120 2017 09 25 1535-7228 2017 Sep 15 The American journal of psychiatry Am J Psychiatry Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. appiajp201717030316 10.1176/appi.ajp.2017.17030316 Apathy is a common behavioral problem in Alzheimer's (...) disease. Apathy has profound consequences, such as functional impairment, higher service utilization, higher caregiver burden, and increased mortality. The authors' objective was to study the effects of methylphenidate on apathy in Alzheimer's disease. A 12-week, prospective, double-blind, randomized, placebo-controlled trial (methylphenidate versus placebo) was conducted in community-dwelling veterans (N=60) with mild Alzheimer's disease. The primary outcome for apathy (Apathy Evaluation Scale

EvidenceUpdates2017

6. Methylphenidate for children and adolescents with autism spectrum disorder.

Methylphenidate for children and adolescents with autism spectrum disorder. BACKGROUND: Children with autistic spectrum disorder (ASD) frequently present with inattention, impulsivity and hyperactivity, which are the cardinal symptoms of attention deficit hyperactivity disorder (ADHD). The effectiveness of methylphenidate, a commonly used ADHD treatment, is therefore of interest in these children. OBJECTIVES: To assess the effects of methylphenidate for symptoms of ADHD (inattention (...) the effect of methylphenidate versus placebo on the core symptoms of ASD or ADHD-like symptoms, or both, in children aged 6 to 18 years who were diagnosed with ASD or pervasive developmental disorder. The primary outcome was clinical efficacy, defined as an improvement in ADHD-like symptoms (inattention, impulsivity and hyperactivity) and in the core symptoms of ASD (impaired social interaction, impaired communication, and stereotypical behaviours), and overall ASD. Secondary outcomes examined were: rate

Cochrane2017

7. Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists

Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists 29354563 2018 11 13 2230-5254 6 2017 Integrated pharmacy research & practice Integr Pharm Res Pract Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists. 163-171 10.2147/IPRP.S142576 Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental (...) condition that affects children, adolescents, and adults worldwide. The purpose of this review was to inform pharmacists of the numerous options to treat ADHD, with a focus on one of the more recently approved formulations, methylphenidate extended-release oral suspension (MEROS). Symptoms of ADHD can negatively impact an individual's health and quality of life and impair function in multiple settings. Psychostimulants such as methylphenidate- and amphetamine-based agents are first-line pharmacologic

Integrated pharmacy research & practice2017 Full Text: Link to full Text with Trip Pro

8. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder Article Text Methods

Evidence-Based Medicine (Requires free registration)2017

9. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. OBJECTIVE: To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. DESIGN: Self controlled case series analysis. SETTING: Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South (...) Korea. PARTICIPANTS: 1224 patients aged ≤17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. MAIN OUTCOME MEASURES: A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63

BMJ2016

10. Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality?

Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ Article Text Perspective Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ O J Storebø , , , M Zwi , H B Krogh , , C R Moreira-Maia , M Holmskov , , D Gillies

Evidence-Based Mental Health2016

11. Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Article Text Perspective Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Tobias Banaschewski , Jan Buitelaar , , Celine S L Chui , David Coghill , Samuele Cortese , , Emily Simonoff

Evidence-Based Mental Health2016

12. Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder

Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder | CADTH.ca Find the information you need Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR (...) and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Published on: September 2, 2015 Project Number: RB0904-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence for the duration of dosage effect for methylphenidate SR and dextroamphetamine SR for patients with attention deficit hyperactivity disorder? Key Message One systematic review, two randomized controlled trials, and two non-randomized studies were

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

13. Methylphenidate: adverse cardiovascular effects

Methylphenidate: adverse cardiovascular effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate: adverse cardiovascular effects '', 1 June 2015 {1} {1} {1} | | > > > Methylphenidate: adverse cardiovascular effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate: adverse cardiovascular effects Methylphenidate (Ritalin° and other (...) brands) exposes patients to severe adverse effects. It should only be envisaged in cases of severe behavioural disorder, at the minimum effective dose and under supervision. Methylphenidate is prescribed for hyperactive children with attention deficit disorder and in some cases of narcolepsy (uncontrollable tendency to fall asleep). Its adverse effects include neuropsychological and cardiovascular disorders, retarded growth in children, abuse and dependence. Methylphenidate belongs to the family

Prescrire2015

14. Methylphenidate

Methylphenidate USE OF METHYLPHENIDATE IN PREGNANCY 0344 892 0909 USE OF METHYLPHENIDATE IN PREGNANCY (Date of issue: March 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Methylphenidate is a central nervous system stimulant (...) used in the management of attention deficit hyperactivity disorder (ADHD). It is also used off license in the treatment of narcolepsy. There are very limited data available on which to base an assessment of the safety of methylphenidate in pregnancy. The existing data regarding therapeutic use of methylphenidate do not suggest a significantly increased risk of congenital malformation or adverse fetal outcome following exposure but are too limited to exclude any increase in risk. As with other CNS

UK Teratology Information Service2014

15. Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy

Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Long-acting versus short-acting methylphenidate for paediatric ADHD: a systematic review and meta-analysis of comparative efficacy Punja S, Zorzela L, Hartling L, Urichuk L, Vohra S CRD summary This review concluded that long-acting (...) methylphenidate had a modest benefit, over short-acting methylphenidate, for attention or overactivity, and hyperactivity or impulsivity, reported by parents, but short-acting methylphenidate was better, for hyperactivity reported by teachers. Discrepancies in ratings, possible overestimated effect sizes, small samples, and no long-term data, mean that these conclusions may not be reliable. Authors' objectives To assess the efficacy and safety of short-acting versus long-acting methylphenidate, to manage

DARE.2013

16. Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability

Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Article Text Children & Adolescents Methylphenidate reduces ADHD symptoms in children with severe ADHD and intellectual disability Statistics from Altmetric.com No Altmetric data available for this article. Question Question

Evidence-Based Mental Health2013

17. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review]

[Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Jang BH, Lee HY, Jung YJ, An JH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Jang BH, Lee HY, Jung YJ, An JH. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-C-12-007. 2012 Authors' conclusions The research was carried out using the basic existing systematic review framework suggested by the Agency for Healthcare Research and Quality (AHRQ 2009

Health Technology Assessment (HTA) Database.2012

18. Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD

Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Article Text Therapeutics Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD

Evidence-Based Mental Health2012

19. Quillivant XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension

Quillivant XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension Drug Approval Package: QUILLIVANT XR (methylphenidate) NDA #202100 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - QUILLIVANT XR (methylphenidate hydrochloride) for Extended-Release Oral Suspension 25 mg per 5 mL Company: NextWave Pharmaceuticals, Inc. Application No.: 202100 Approval Date: 09/27/2012 Persons with disabilities having problems accessing the PDF

FDA - Drug Approval Package2012

20. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children (...) and adolescents: a meta-analysis Hanwella R, Senanayake M, de Silva V CRD summary The review found that methylphenidate and atomoxetine have comparable efficacy and acceptability for treating attention deficit hyperactivity disorder in children and adolescents but that osmotically-released methylphenidate was more effective than atomoxetine. The authors' conclusions require some caution due to limitations in the review, including insufficient information about study quality, potential publication bias

DARE.2011